Kennedy A R
University of Pennsylvania School of Medicine, Philadelphia, USA.
Am J Clin Nutr. 1998 Dec;68(6 Suppl):1406S-1412S. doi: 10.1093/ajcn/68.6.1406S.
Certain protease inhibitors are effective at preventing or suppressing carcinogen-induced transformation in vitro and carcinogenesis in animal model systems. One protease inhibitor, the soybean-derived Bowman-Birk inhibitor (BBI) is particularly effective in suppressing carcinogenesis. BBI is a protein of a molecular weight of 8000 with a well-characterized ability to inhibit trypsin and chymotrypsin. BBI has been extensively studied, both as purified BBI and as an extract of soybeans enriched in BBI called BBI concentrate (BBIC). Purified BBI and BBIC have comparable suppressive effects on the carcinogenic process in a variety of in vivo and in vitro systems. BBI appears to be a universal cancer preventive agent. Purified BBI and BBIC suppress carcinogenesis as follows: in 3 different species (mice, rats, and hamsters); in several organ systems and tissue types [eg, colon, liver, lung, esophagus, cheek pouch (oral epithelium), and cells of hematopoietic origin]; and in cells of epithelial and connective tissue origin when given to animals by several different routes of administration, including the diet, leading to different types of cancer (eg, squamous cell carcinomas, adenocarcinomas, and angiosarcomas), and induced by various chemical and physical carcinogens. About half of an oral dose of BBI is taken up into the bloodstream and distributed throughout the body, with excretion via the urine. Pharmacokinetic studies of BBI have been performed in animals with radioactively labeled BBI, whereas antibodies that react with reduced BBI are being used in pharmacokinetic studies in humans. The calculated serum half-life is 10 h in both rats and hamsters. BBIC achieved Investigational New Drug status from the FDA in April 1992 (IND no. 34671; sponsor, Ann R Kennedy), and studies to evaluate BBIC as an anticarcinogenic agent in human populations began. Both BBI and BBIC prevent and suppress malignant transformation in vitro and carcinogenesis in vivo without toxicity.
某些蛋白酶抑制剂在体外可有效预防或抑制致癌物诱导的细胞转化,并在动物模型系统中抑制致癌作用。一种蛋白酶抑制剂,即大豆来源的鲍曼-伯克抑制剂(BBI),在抑制致癌作用方面特别有效。BBI是一种分子量为8000的蛋白质,具有明确的抑制胰蛋白酶和糜蛋白酶的能力。BBI已得到广泛研究,包括纯化的BBI以及富含BBI的大豆提取物(称为BBI浓缩物,BBIC)。纯化的BBI和BBIC在多种体内和体外系统中对致癌过程具有相当的抑制作用。BBI似乎是一种通用的癌症预防剂。纯化的BBI和BBIC通过以下方式抑制致癌作用:在3种不同物种(小鼠、大鼠和仓鼠)中;在多个器官系统和组织类型中[例如,结肠、肝脏、肺、食管、颊囊(口腔上皮)以及造血来源的细胞];以及当通过多种不同给药途径(包括饮食)给予动物时,在上皮和结缔组织来源的细胞中,可导致不同类型的癌症(例如,鳞状细胞癌、腺癌和血管肉瘤),且由各种化学和物理致癌物诱导。口服剂量的BBI约有一半会被吸收进入血液并分布至全身,通过尿液排泄。已使用放射性标记的BBI在动物中进行了BBI的药代动力学研究,而与还原型BBI反应的抗体正被用于人体药代动力学研究。在大鼠和仓鼠中计算出的血清半衰期均为10小时。BBIC于1992年4月获得美国食品药品监督管理局(FDA)的研究性新药地位(IND编号34671;申办者为安·R·肯尼迪),并开始了评估BBIC作为人类抗癌剂的研究。BBI和BBIC均可预防和抑制体外恶性转化及体内致癌作用,且无毒性。